ClinicalTrials.gg
Status unknownNCT03307720Updated Dec 11, 2017

Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)

An interventional study of Gonadotropin Releasing Hormone Agonists (GNRH-A) and Human chorionic gonadotropin in Ovulation Induction, In Vitro Fertilization (IVF) and Infertility, Female, sponsored by Ginegorama S.L.. Status unknown at 1 site in Spain. Open to female participants aged 18 Years to 48 Years. Per ClinicalTrials.gov, last updated 2017-12-11.

Sponsored by Ginegorama S.L. · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 48 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Infertility, Female with a site in Spain — 8 open to participants now, 8 under way, none of them phase 3. Infertility, Female · Spain.

Planned enrollment
5th of 26
300 · median 94
Started
2017
with 4 others
No phase
16 of 33
6 open now
Registered
10th of 33
by date

Among the 33 studies in Infertility, Female with a site in Spain, this one is the 5th largest by planned enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2017, is one of 16 with no phase, and was the 10th registered.

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

8 of the 33 studies in Infertility, Female with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 48 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Infertility, Female with a site in Spain, or all of them as a file.
02

Study summary

Agonist triggering in controlled ovarian stimulation protocols is being used during last years (among high responder patients to avoid OHSS).

Indeed, agonist triggering is more physiologic than HCG triggering. Investigators propose to compare the effectiveness of both types of trigger among three different subsets of patients:

  1. Poor responders.
  2. Normo-responders
  3. High responders Comparing both the number and the quality of achieved oocytes.
Read the detailed description

During the last years, ovulation triggering in controlled ovarian stimulation protocols has been used specially to avoid hyperstimulation syndromes (OHSS). Indeed, the substitution of the classical HCG triggering by the agonist one, reduces almost to zero the risk of OHSS.

On the other hand poor responder patients to ovarian stimulation represent a challenge in assisted reproduction. Defining poor responders is not easy, but we can define them as those patients with less than 4 eggs obtained after oocyte retrieval.

Different strategies have been proposed to overcome this problem. In other words, to obtain more oocytes. These include an increase in FSH doses, an increase in FSH action by adding sensitizers agents.

Among the possible strategies, investigators propose the agonist triggering. HCG (classical) triggering represents the use of a LH-like product (with a prolonged action). The administration of a GnRH agonist provoke the production and liberation of both FSH and LH. Thus, the pro-ovulatory action is more physiologic , and possibly, more effective.

So, the use of a triggering protocol that nowadays is being used among high responders (thus reducing the OHSS risk) is proposed for both poor responder and normo-responder patients trying to achieve more oocytes, and specifically more mature oocytes.

03

Conditions studied

  • Ovulation Induction
  • In Vitro Fertilization (IVF)
  • Infertility, Female
  • Oocytes

Browse trials for

Keywords

  • agonist trigger
  • Ovulation induction
  • Controlled ovarian stimulation (COS)
  • Poor responder
04

Who can participate

Ages eligible
18 Years to 48 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women scheduled for IVF treatment.
  • First ovarian stimulation
  • Two ovaries present
  • No previous ovarian surgery
  • No for any of the assigned treatments

Exclusion criteria

Exclusion Criteria:

  • Previous ovarian surgery.
  • Previous IVF treatments.
  • Absence of one ovary
  • Presence of an endometrioma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Poor responders. Classical trigger

    Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval. Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment.

    Drug: Human chorionic gonadotropin

  • Experimental
    Poor responders. Agonist trigger

    Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval) Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment.

    Drug: Gonadotropin Releasing Hormone Agonists (GNRH-A)

  • Active comparator
    Normo responders. Classical trigger

    Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval. Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment.

    Drug: Human chorionic gonadotropin

  • Experimental
    Normo responders. Agonist trigger

    Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval) Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment.

    Drug: Gonadotropin Releasing Hormone Agonists (GNRH-A)

  • Active comparator
    High responders. Classical trigger

    Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval. Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment.

    Drug: Human chorionic gonadotropin

  • Experimental
    High responders. Agonist trigger

    Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval) Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment.

    Drug: Gonadotropin Releasing Hormone Agonists (GNRH-A)

Interventions

  • DrugGonadotropin Releasing Hormone Agonists (GNRH-A)

    Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.

    Also known as: Agonist trigger

  • Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.

    Also known as: HCG trigger

06

What researchers measure

Primary outcomes

  1. Mature oocytes

    Number of mature oocytes achieved after oocyte retrieval.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Relation mature oocytes/punctured oocytes

    Relation between the number of mature oocytes and the follicles.

    Time frame: Up to 24 weeks

  2. Fertilized oocytes

    Number of fertilized oocytes

    Time frame: Up to 24 weeks

  3. Relation fertilized oocytes/achieved Mature oocytes

    Relation between the number of fertilized oocytes and the mature oocytes achieved.

    Time frame: Up to 24 weeks

  4. Number of blastocysts developed

    Number of blastocysts developed in each arm of the study.

    Time frame: Up to 24 weeks

  5. Cancelled cycles

    Percentage of cancelled cycles

    Time frame: Up to 24 weeks

07

Study locations

1 site
  • Reproduccion Bilbao Assisted Reproduction Center
    Bilbao, Bizkaia 48014, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2017; primary completion for Feb 2018, 2 months later.

Of 142 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 2 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2017
First posted
Oct 12, 2017
StartEst.
Dec 18, 2017
Primary completionEst.
Feb 2018
CompletionEst.
May 2018
Last update
Dec 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03307720
Lead sponsor
Ginegorama S.L.
Responsible party
Gorka Barrenetxea (Professor of Gynecology & Obstetrics Universidad del País Vasco/Euskal Herriko Unibertsitatea. Medical Director of Reproducción Bilbao, Ginegorama S.L.) — Principal investigator
First posted
Oct 12, 2017
Start date
Dec 18, 2017 (estimated)
Primary completion
Feb 2018 (estimated)
Completion
May 2018 (estimated)
Last update
Dec 11, 2017

Study contacts

Gorka Barrenetxea, PhD
Contact
gbarrenetxea@reproduccionbilbao.es
00 34 605711484
Amaia Garcia, PhD
Contact
agarcia@reproduccionbilbao.es
Gorka Barrenetxea, PhD
principal investigator · Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea
Jon Iker Arambarri, MD
study chair · Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion